

Freeware & Open Access Databases

Towards a Wiki Drug Discovery?

Is it possible to use “free” accessible information to run a drug design project?



BACKGROUND

i&os

WHAT DO WE NEED?

- 1.What
- 2.Where
- 3.How
- 4.Example
- 5.Reference



WHAT DO WE NEED?

- 1.Drug Design
- 2.Information
- 3.Mining
- 4.Zika
- 5.Reference

FREE VS COMMERCIAL



FREE vs COMMERCIAL

Free / Open Source Systems



Commercial Systems



WHAT DO WE NEED?



- 1.What
- 2.Where
- 3.How
- 4.Example
- 5.Reference



The Big Picture




DRUG DISCOVERY & MOLECULAR PROPERTIES



DRUG DISCOVERY & MOLECULAR PROPERTIES




DRUG DISCOVERY & MOLECULAR PROPERTIES





TISSUE/ORGAN DISTRIBUTION

DRUG DISCOVERY & MOLECULAR PROPERTIES




CELLULAR PERMEABILITY


DRUG DISCOVERY & MOLECULAR PROPERTIES



BIND TO RECEPTOR



DRUG DISCOVERY & MOLECULAR PROPERTIES



ELIMINATION

Pharmaco-kinetics & Pharmaco-dynamics

ENTER SYSTEMIC CIRCULATION
(ABSORPTION)

TISSUE/ORGAN DISTRIBUTION

CELLULAR PERMEABILITY

BIND TO RECEPTOR


ELIMINATION

Chemical & Biological properties

STRUCTURAL PROPERTIES

BIOLOGICAL PROPERTIES
(measured)

PHYSICO CHEMICAL PROPERTIES
(calculated)



DRUG DISCOVERY & MOLECULAR PROPERTIES

Pharmaco-kinetics & Pharmaco-dynamics

ENTER SYSTEMIC CIRCULATION
(ABSORPTION)

TISSUE/ORGAN DISTRIBUTION

CELLULAR PERMEABILITY

BIND TO RECEPTOR


ELIMINATION

Chemical & Biological properties


STRUCTURAL PROPERTIES

BIOLOGICAL PROPERTIES
(measured)

PHYSICO CHEMICAL PROPERTIES
(calculated)





Med Chem Properties




Data Mining

Available information (building correlations)



★ New Potential Candidate Drug



one more thing...



one more thing...




Nature



Analogy



HTS



Chemical Evolution



Structures and associated data

WHERE TO FIND THE INFORMATION

1.What

2.Where

3.How

4.Example

5.Reference

Information Sources (open access)

- easy integration with analytical platforms (free and commercial)
- most popular (and up to date)



... and many more

i/o s

WHERE TO FIND THE INFORMATION

1.What

2.Where

3.How

4.Example

5.Reference



- Free
- NCBI
- FTP / API
- BioAssay / Compounds

WHAT DO WE NEED?

1.What

2.Where

3.How

4.Example

5.Reference

Data Mining & Visualization (*open access*)

www.predictiveanalyticstoday.com



WHAT DO WE NEED?

- 1.What
- 2.Where
- 3.How
- 4.Example
- 5.Reference


Data Mining & Visualization (*open access*)



- Popular
- User community
- Integration
- Compounds & reactions
- Flexible (applications)


WHAT DO WE NEED?

- 1.What
- 2.Where
- 3.How
- 4.Example
- 5.Reference




... we do not have own data to compare with...


WHAT DO WE NEED?



Nexium®



Rabeprazole®



Pantoprazole®


1.What

2.Where


3.How

4.Example


5.Reference




Loxapine®




Seroquel®




Norfloxacin
(Noroxin™)



Ciprofloxacin
(Cipro™)



Grepafloxacin
(Raxar™)




Sparfloxacin
(Zagam™)

WHAT DO WE NEED?

- 1.What
- 2.Where
- 3.How
- 4.Example
- 5.Reference

STRUCTURAL ANALYSIS

+ ASSOCIATED DATA




... we do not have own data to compare with...

WHAT DO WE NEED?

- 1.What
- 2.Where
- 3.How
- 4.Example
- 5.Reference


- ▣ Spread by the bite of *Aedes* species mosquito
- ▣ Harmless symptoms
- ▣ Transferred to fetus (birth defects)
- ▣ 1947 and 2016
- ▣ No vaccine / medicine



www.healthmap.org

ZIKA: OPEN ACCESS DRUG DISCOVERY PROJECT

- Collection of biological & chemical data
- 464 potential drug targets
- Direct mining possible (not straightforward)
- Download data for external mining



www.nature.com/scientificreports/ (DOI: 10.1038/srep32713)

www.openzika.ufg.br

<http://bioinfo.imtech.res.in/manojk/zikavr/index.php>



ZIKA: OPEN ACCESS DRUG DISCOVERY PROJECT

■ 3 main biological targets:


- Interleukin-4-receptor subunit alpha
- Genome polyprotein
- Kinesin-like protein KIF11

■ 1 structural “coincidence”


- 6 Molecules share the same subgraph




ZIKA: OPEN ACCESS DRUG DISCOVERY PROJECT



Emricasan



PHA-690509



Niclosamide

- pan-caspase inhibitor
- neuroprotective activity
- not suppress ZIKV replication

- cyclic-dependent kinase inhibitor (CDKi)*
- antiviral activity

- FDA-approved drug
- treatment of worm infections

*Ten structurally unrelated CDKis inhibit ZIKA replication


Combination of Drugs

Taken together ...

<http://bioinfo.imtech.res.in/manojk/zikavr/index.php>

Nature Medicine 22, 10, 2016, 1101

1 structural “coincidence”



- Interleukin-4-receptor subunit alpha
- Genome polyprotein
- Kinesin-like protein KIF11


cyclic-dependent kinase inhibitor (CDKi)

Ten structurally unrelated CDKis inhibit ZIKA replication


1. Search bioactives related to the subgraph
2. Search for KIF11 inhibitors (Structural comparison)
3. Search for CDK inhibitors (Structural comparison)

<http://www.pharmakarma.org/>

CDKi's (27 molecules)



4/27





11/27



13/27

Ten structurally unrelated CDKis inhibit ZIKA replication

**257 structurally unrelated CDKi's
(based on subgraph)**




...structures and bio-assay data available

1452 CDKi's found (CDK1-CDK20)

ZIKA: OPEN ACCESS DRUG DISCOVERY PROJECT

14 Molecules in www.drugbank.ca

1 structural “coincidence”




6/14

- Interleukin-4-receptor subunit alpha
- Genome polyprotein
- Kinesin-like protein KIF11

7/14

KIF11 inhibitors found:



0/5776

Graph analogues found:

1100

- 18 reported as Kinesin like protein 1
- Kinesin superfamily (non-standard names)
- >1000 compounds (Tanimoto >0.7)

<http://bioinfo.imtech.res.in/manojk/zikavr/index.php>

<http://www.pharmakarma.org/>


Summary

- **Analogues with same subgraph (Tanimoto >0.7)**
- **Non related structures active on same targets**
- **Bioassay data**
- **Other analysis possible**
 - ▣ Lipinski
 - ▣ Pharmacophore
 - ▣ Match Pairs
 - ▣ SAR
 - ▣ R-Group Decomposition

WHAT DO WE NEED?

- 1.What
- 2.Where
- 3.How
- 4.Example
- 5.Reference

REAXYS API



WHAT DO WE NEED?

- 1.What
- 2.Where
- 3.How
- 4.Example
- 5.Reference

REAXYS API

- CDKi's ca 40000 structures (25x more)
- KIF11 inhibitors ca 4000 structures (1000 less)
- Equal amount of data
- Same conclusions

Is it possible to use “free” accessible information to run a drug design project?

YES



but ...

- Quality
- Accessibility
- Up to Date

OUR ANSWERS

Towards a Wiki Drug Discovery?

YES

- ▣ Neglected diseases (Malaria)
- ▣ Orphan diseases
- ▣ Unmet medical needs

NO

- ▣ All others

Katherine
HEIGL

Gerard
BUTLER



the**ugly**truth

In Theaters July 24th
TheUglyTruth-movie.com

© 2009 SONY PICTURES DIGITAL INC. ALL RIGHTS RESERVED.

i&os

FREE vs COMMERCIAL

Free / Open Source Systems



Commercial Systems



YOUR TASTE!
YOUR NEEDS!

i/o s